STOCK TITAN

[Form 4] INTEGRA LIFESCIENCES HOLDINGS CORP Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4

Integra LifeSciences (IART) reported an insider equity event. EVP & President, International Harvinder Singh vested 11,965 restricted stock units on 10/12/2025, which settled into common stock. To cover taxes, 3,281 shares were withheld at $13.34, and the reporting person retained 8,684 shares from the vesting. Following these transactions, direct beneficial ownership stood at 21,936 common shares.

The RSU award vested in full on the third anniversary of its grant date (10/12/2022). Derivative securities beneficially owned following the event were 22,566 RSUs.

Integra LifeSciences (IART) ha riportato un evento azionario di insider. Il vicepresidente esecutivo e presidente, International Harvinder Singh, ha maturato 11.965 unità azionarie vincolate (RSU) il 10/12/2025, che sono state liquidate in azioni ordinarie. Per coprire le tasse, 3.281 azioni sono state trattenute al prezzo di $13.34, e la persona riportante ha conservato 8.684 azioni dalla vesting. Dopo queste transazioni, la proprietà diretta vantata ammontava a 21.936 azioni ordinarie.

L'assegnazione RSU è maturata interamente al terzo anniversario dalla data di concessione (10/12/2022). Le azioni dello strumento derivato di proprietà dopo l'evento erano 22.566 RSU.

Integra LifeSciences (IART) informó un evento de equidad de insider. El vicepresidente ejecutivo y presidente, International Harvinder Singh, adquirió 11,965 unidades restringidas de acciones (RSU) el 12/10/2025, que se liquidaron en acciones comunes. Para cubrir impuestos, se retuvieron 3,281 acciones a $13.34, y la persona reportante retuvo 8,684 acciones de la adjudicación. Tras estas transacciones, la propiedad beneficiaria directa fue de 21,936 acciones comunes.

El otorgamiento RSU se venció por completo al tercer aniversario de la fecha de concesión (12/10/2022). Los valores mobiliarios derivados poseídos de forma beneficiosa tras el evento eran 22,566 RSU.

Integra LifeSciences (IART)은 내부자 자본 이벤트를 보고했습니다. EVP 겸 국제 부문 사장인 Harvinder Singh은 11,965개의 제한 주식 단위(RSU)를 2025-10-12에 취득했고, 이는 일반 주식으로 정착되었습니다. 세금 납부를 위해 3,281주가 $13.34로 원천징수되었으며, 보고자는 수여 vesting에서 8,684주를 보유했습니다. 이 거래 후 직접적인 유익 소유는 21,936주 일반 주식으로 남았습니다.

RSU 보상은 수여일의 3주년에 전체적으로 취득되었습니다(2022-10-12). 행사 이후 실질적으로 소유한 파생 증권은 22,566 RSU였습니다.

Integra LifeSciences (IART) a signalé un événement d'actionnariat interne. Le vice-président exécutif et président International, Harvinder Singh, a acquis 11 965 unités d'actions restreintes (RSU) le 12/10/2025, qui ont été converties en actions ordinaires. Pour couvrir les impôts, 3 281 actions ont été retenues à $13.34, et la personne déclarante a conservé 8 684 actions issues vesting. Après ces transactions, la propriété bénéficiaire directe s'élevait à 21 936 actions ordinaires.

L'attribution RSU s'est entièrement acquise au troisième anniversaire de la date d'octroi (12/10/2022). Les valeurs mobilières dérivées détenues de manière bénéficiaire après l'événement étaient 22 566 RSU.

Integra LifeSciences (IART) meldete ein Insider-Eigenkapitalereignis. Der EVP & Präsident, International, Harvinder Singh, verteilte 11.965 Restricted Stock Units (RSU) am 10.12.2025, die in Stammaktien umgewandelt wurden. Um Steuern abzudecken, wurden 3.281 Aktien zum Preis von $13,34 einbehalten, und die meldende Person behielt 8.684 Aktien aus dem Vesting. Nach diesen Transaktionen betrug die direkte begünstigte Eigentümerschaft 21.936 Stammaktien.

Der RSU-Berechtigungsbetrag war am dritten Jahrestag des Gewährungsdatums vollständig vestet (12.10.2022). Rechtsverbindlich gehaltene Derivate nach dem Ereignis betrugen 22.566 RSUs.

Integra LifeSciences (IART) أبلغت عن حدث أسهم داخلي. نائب الرئيس التنفيذي والرئيس الدولي، هارفيندر سينغ، منح 11,965 وحدة أسهم مقيدة (RSU) في 12/10/2025، والتي جرى تسويتها إلى أسهم عادية. لتغطية الضرائب، تم حجز 3,281 سهمًا بالسعر $13.34، واحتفظ الشخص المبلّغ له بـ 8,684 سهمًا من vesting. بعد هذه المعاملات، بلغت الملكية المباشرة المفيدة 21,936 سهمًا عاديًا.

تم تسوية منح RSU بالكامل في السنة الثالثة من تاريخ المنح (12/10/2022). الأوراق المالية المشتقة المحقّة بعد الحدث كانت 22,566 RSU.

Integra LifeSciences (IART) 报告了一起内部交易事件。国际业务总裁兼执行副总裁 Harvinder Singh 于 2025-10-12 授予了 11,965 份受限股票单位(RSU),已结算为普通股。为覆盖税款,3,281 股按 $13.34 的价格被预扣,报告人保留了 vesting 产生的 8,684 股。此后,直接受益所有权为 21,936 股普通股。

RSU 授予在授予日的第三周年时完全归属(2022-10-12)。事件后实际持有的衍生证券为 22,566 RSU。

Positive
  • None.
Negative
  • None.

Integra LifeSciences (IART) ha riportato un evento azionario di insider. Il vicepresidente esecutivo e presidente, International Harvinder Singh, ha maturato 11.965 unità azionarie vincolate (RSU) il 10/12/2025, che sono state liquidate in azioni ordinarie. Per coprire le tasse, 3.281 azioni sono state trattenute al prezzo di $13.34, e la persona riportante ha conservato 8.684 azioni dalla vesting. Dopo queste transazioni, la proprietà diretta vantata ammontava a 21.936 azioni ordinarie.

L'assegnazione RSU è maturata interamente al terzo anniversario dalla data di concessione (10/12/2022). Le azioni dello strumento derivato di proprietà dopo l'evento erano 22.566 RSU.

Integra LifeSciences (IART) informó un evento de equidad de insider. El vicepresidente ejecutivo y presidente, International Harvinder Singh, adquirió 11,965 unidades restringidas de acciones (RSU) el 12/10/2025, que se liquidaron en acciones comunes. Para cubrir impuestos, se retuvieron 3,281 acciones a $13.34, y la persona reportante retuvo 8,684 acciones de la adjudicación. Tras estas transacciones, la propiedad beneficiaria directa fue de 21,936 acciones comunes.

El otorgamiento RSU se venció por completo al tercer aniversario de la fecha de concesión (12/10/2022). Los valores mobiliarios derivados poseídos de forma beneficiosa tras el evento eran 22,566 RSU.

Integra LifeSciences (IART)은 내부자 자본 이벤트를 보고했습니다. EVP 겸 국제 부문 사장인 Harvinder Singh은 11,965개의 제한 주식 단위(RSU)를 2025-10-12에 취득했고, 이는 일반 주식으로 정착되었습니다. 세금 납부를 위해 3,281주가 $13.34로 원천징수되었으며, 보고자는 수여 vesting에서 8,684주를 보유했습니다. 이 거래 후 직접적인 유익 소유는 21,936주 일반 주식으로 남았습니다.

RSU 보상은 수여일의 3주년에 전체적으로 취득되었습니다(2022-10-12). 행사 이후 실질적으로 소유한 파생 증권은 22,566 RSU였습니다.

Integra LifeSciences (IART) a signalé un événement d'actionnariat interne. Le vice-président exécutif et président International, Harvinder Singh, a acquis 11 965 unités d'actions restreintes (RSU) le 12/10/2025, qui ont été converties en actions ordinaires. Pour couvrir les impôts, 3 281 actions ont été retenues à $13.34, et la personne déclarante a conservé 8 684 actions issues vesting. Après ces transactions, la propriété bénéficiaire directe s'élevait à 21 936 actions ordinaires.

L'attribution RSU s'est entièrement acquise au troisième anniversaire de la date d'octroi (12/10/2022). Les valeurs mobilières dérivées détenues de manière bénéficiaire après l'événement étaient 22 566 RSU.

Integra LifeSciences (IART) meldete ein Insider-Eigenkapitalereignis. Der EVP & Präsident, International, Harvinder Singh, verteilte 11.965 Restricted Stock Units (RSU) am 10.12.2025, die in Stammaktien umgewandelt wurden. Um Steuern abzudecken, wurden 3.281 Aktien zum Preis von $13,34 einbehalten, und die meldende Person behielt 8.684 Aktien aus dem Vesting. Nach diesen Transaktionen betrug die direkte begünstigte Eigentümerschaft 21.936 Stammaktien.

Der RSU-Berechtigungsbetrag war am dritten Jahrestag des Gewährungsdatums vollständig vestet (12.10.2022). Rechtsverbindlich gehaltene Derivate nach dem Ereignis betrugen 22.566 RSUs.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Singh Harvinder

(Last) (First) (Middle)
1100 CAMPUS ROAD

(Street)
PRINCETON NJ 08540

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
INTEGRA LIFESCIENCES HOLDINGS CORP [ IART ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP & PRESIDENT, INTERNATIONAL
3. Date of Earliest Transaction (Month/Day/Year)
10/12/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/12/2025 M 11,965 A $0 25,217 D
Common Stock 10/12/2025 F 3,281(1) D $13.34 21,936 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units $0 10/12/2025 M 11,965 (2) (2) Common Stock 11,965 $0 22,566 D
Explanation of Responses:
1. Represents shares withheld to satisfy the reporting person's tax withholding obligation with respect to 11,965 shares of common stock issued upon the vesting of time based restricted stock units on October 12, 2025. The reporting person retained the remaining 8,684 shares.
2. The award was a restricted stock unit award which vested in full on the third anniversary of the grant date of 10/12/2022.
Remarks:
/s/ Lesha Shinn; Attorney-in-Fact for Harvinder Singh 10/14/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did IART disclose in this Form 4?

An officer reported the vesting of 11,965 RSUs on 10/12/2025 and related share withholding for taxes.

Who is the reporting person and role at IART?

Harvinder Singh, EVP & President, International.

How many shares were withheld for taxes and at what price?

3,281 shares were withheld at $13.34 per share.

How many shares did the officer retain from the vesting?

The officer retained 8,684 shares issued upon RSU vesting.

What is the officer’s direct beneficial ownership after the transactions?

Direct beneficial ownership is 21,936 common shares.

When did the RSU award vest and what was the grant date?

It vested in full on 10/12/2025, the third anniversary of the 10/12/2022 grant.

How many derivative securities (RSUs) remain beneficially owned?

Derivative securities beneficially owned following the transactions total 22,566 RSUs.
Integra Lifesciences Hldgs Cp

NASDAQ:IART

IART Rankings

IART Latest News

IART Latest SEC Filings

IART Stock Data

1.14B
66.91M
13.97%
95.31%
9.23%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
PRINCETON